ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Parenchymal CSF fraction is a measure of brain glymphatic clearance and positively associated with amyloid beta deposition on PET.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Advances in gait research related to Alzheimer's disease.Frontiers in neurology · 2025Pooled it
- Female vulnerability to microvascular transport dysfunction emerges early across the Alzheimer's disease continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Increased MRI-derived parenchymal cerebral spinal fluid mapping in untreated obstructive sleep apnea patients.Neurobiology of disease · 2026Article
- The glymphatic system in neurodegenerative diseases and brain tumors: mechanistic insights, biomarker advances, and therapeutic opportunities.Acta neuropathologica communications · 2025Review
- Article
- Interrater and intrarater reliability of aqueduct CSF flow parameters measured by phase-contrast MRI in healthy adults.Quantitative imaging in medicine and surgery · 2025Article
- PET Imaging of Neurofluids.Neuroimaging clinics of North America · 2025Review
- Transmantle pressure under the influence of free breathing: non-invasive quantification of the aqueduct pressure gradient in healthy adults.Fluids and barriers of the CNS · 2025Article
- Region-informed machine learning model for choroid plexus segmentation in Alzheimer's disease.Frontiers in aging neuroscience · 2025Article
- Brain glymphatic fluid mapping in Alzheimer's disease: a human MRI and PET study.Brain communications · 2025Article
- Editorial: CSF clearance in Alzheimer's disease and related dementias: exploring mechanisms and implications.Frontiers in aging neuroscience · 2025Article
- Research hotspots and frontiers of glymphatic system and Alzheimer's disease: a bibliometrics analysis.Frontiers in aging neuroscience · 2025Article
- Quantitative transport mapping of multi-delay arterial spin labeling MRI detects early blood perfusion alterations in Alzheimer's disease.Alzheimer's research & therapy · 2024Article
- Quantitative transport mapping of multi-delay arterial spin labeling MRI detects early blood perfusion alteration in Alzheimer's disease.medRxiv : the preprint server for health sciences · 2024Article
- Parenchymal CSF fraction is a measure of brain glymphatic clearance and positively associated with amyloid beta deposition on PET.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Comprehensive and stratified meta-analysis of diffusion tensor image analysis along the perivascular space in Alzheimer's disease: Linking glymphatic dysfunction with cognitive decline and amyloid pathology.Journal of Alzheimer's disease reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
introductionMapping of microscopic changes in the perivascular space (PVS) of the cerebral cortex, beyond magnetic resonance-visible PVS in white matter, may enhance our ability to diagnose Alzheimer's disease (AD) early.
methodsWe used the cerebrospinal fluid (CSF) water fraction (CSFF), a magnetic resonance imaging-based biomarker, to characterize brain parenchymal CSF water, reflecting microscopic PVS in parenchyma. We measured CSFF and amyloid beta (Aβ) using
resultsOur research has demonstrated a positive correlation between the parenchymal CSFF, a non-invasive imaging biomarker indicative of parenchymal glymphatic clearance, and Aβ deposition, observed at both individual and voxel-based assessments in the posterior cingulate cortex. DISCUSSION: This study shows that an increased parenchymal CSFF is associated with Aβ deposition, suggesting that CSFF could serve as a biomarker for brain glymphatic clearance, which can be used to detect early fluid changes in PVS predisposing individuals to the development of AD. HIGHLIGHTS: Cerebrospinal fluid fraction (CSFF) could be a biomarker of parenchymal perivascular space. CSFF is positively associated with amyloid beta (Aβ) deposition at subject level. CSFF in an Aβ+ region is higher than in an Aβ- region in the posterior cingulate cortex. Correspondence is found between Aβ deposition and glymphatic clearance deficits measured by CSFF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.